Raymond James & Associates Krystal Biotech, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 2,861 shares of KRYS stock, worth $523,820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,861
Previous 2,829
1.13%
Holding current value
$523,820
Previous $519,000
0.19%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding KRYS
# of Institutions
278Shares Held
24.9MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$723 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$525 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$445 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$244 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$187 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.7B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...